title: GPI-15715 Guilford.
abstract: GPI-15715 (PQ-1002, Aquavan), a water-soluble prodrug of propofol, is being developed by Guilford, under license from ProQuest, as a potential anesthetic agent. In May 2004, Guilford initiated phase III trials in the US to evaluate the sedative effects of this prodrug in several patient populations.
authors.affiliation: Committee on Clinical Pharmacology & Pharmacogenomics and Department of Pathology, University of Chicago, Chicago, IL 60637, USA. kra3@harper.uchicago.edu
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Krasowski
mesh_terms: D018686:Anesthetics, Intravenous / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D011355:Prodrugs / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015742:Propofol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D018686:Anesthetics, Intravenous; D011355:Prodrugs; C472965:fospropofol; D015742:Propofol